Skip to Content

JHancock Multimanager 2025 Lifetime R4 JLEGX Fund Analysis

| Analyst rating as of | See John Hancock Investment Hub

Morningstar’s Analysis JLEGX

Will JLEGX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

A pricey and complex target-date offering.



John Hancock Multimanager Lifetime target-date series’ complex approach and above average fees make it less appealing for retirement savers. The series maintains its Morningstar Analyst Rating of Neutral across all share classes.

Unlock our full analysis with Morningstar Investor